The Washington University Tuberous Sclerosis Center conducts basic laboratory research on the biological basis of TSC, focusing on the neurological manifestations, such as epilepsy. The ultimate goal of this laboratory research is to develop new therapies for patients with TSC.
Research conducted in the Center has been funded by the National Institutes of Health, Department of Defense, and private foundations, such as the Tuberous Sclerosis Alliance. Basic research performed at our Center provided critical preclinical data leading to clinical trials and subsequent FDA approval of mTOR inhibitors for epilepsy in TSC patients. We are also collaborating with the Tuberous Sclerosis Alliance on the TSC Preclinical Consortium, which facilitates new drug development for TSC.
For more information about basic science research on TSC done in this center, see the Wong Laboratory website.